How antidepressants help depression: Mechanisms of action and clinical response

Pedro L. Delgado

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The monoamine hypothesis of depression suggests that depressive symptoms can be moderated by enhancing monoamine neurotransmission. Targeted neurotransmitters include serotonin and norepinephrine, and a number of medications are available that can selectively enhance the actions of one or both of these substances. Although laboratory tests have validated the pharmacologic effects of these compounds, much less is known about how these effects translate into clinical response. Therapeutic research and experience show clearly that the medications help patients, although the individual and potential cooperative or complementary effects of stimulating each neurotransmitter system remain unclear. Depletion studies have reinforced the validity of targeting these systems and, at the same time, underscored that monoamines most likely are not the only factor driving the clinical presentation of depression.

Original languageEnglish (US)
Pages (from-to)25-30
Number of pages6
JournalJournal of Clinical Psychiatry
Volume65
Issue numberSUPPL. 4
StatePublished - 2004
Externally publishedYes

Fingerprint

Antidepressive Agents
Depression
Neurotransmitter Agents
Therapeutic Human Experimentation
Synaptic Transmission
Serotonin
Norepinephrine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

How antidepressants help depression : Mechanisms of action and clinical response. / Delgado, Pedro L.

In: Journal of Clinical Psychiatry, Vol. 65, No. SUPPL. 4, 2004, p. 25-30.

Research output: Contribution to journalArticle

@article{0723642b1adf4440948f65c9c3ca9d90,
title = "How antidepressants help depression: Mechanisms of action and clinical response",
abstract = "The monoamine hypothesis of depression suggests that depressive symptoms can be moderated by enhancing monoamine neurotransmission. Targeted neurotransmitters include serotonin and norepinephrine, and a number of medications are available that can selectively enhance the actions of one or both of these substances. Although laboratory tests have validated the pharmacologic effects of these compounds, much less is known about how these effects translate into clinical response. Therapeutic research and experience show clearly that the medications help patients, although the individual and potential cooperative or complementary effects of stimulating each neurotransmitter system remain unclear. Depletion studies have reinforced the validity of targeting these systems and, at the same time, underscored that monoamines most likely are not the only factor driving the clinical presentation of depression.",
author = "Delgado, {Pedro L.}",
year = "2004",
language = "English (US)",
volume = "65",
pages = "25--30",
journal = "The Journal of clinical psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 4",

}

TY - JOUR

T1 - How antidepressants help depression

T2 - Mechanisms of action and clinical response

AU - Delgado, Pedro L.

PY - 2004

Y1 - 2004

N2 - The monoamine hypothesis of depression suggests that depressive symptoms can be moderated by enhancing monoamine neurotransmission. Targeted neurotransmitters include serotonin and norepinephrine, and a number of medications are available that can selectively enhance the actions of one or both of these substances. Although laboratory tests have validated the pharmacologic effects of these compounds, much less is known about how these effects translate into clinical response. Therapeutic research and experience show clearly that the medications help patients, although the individual and potential cooperative or complementary effects of stimulating each neurotransmitter system remain unclear. Depletion studies have reinforced the validity of targeting these systems and, at the same time, underscored that monoamines most likely are not the only factor driving the clinical presentation of depression.

AB - The monoamine hypothesis of depression suggests that depressive symptoms can be moderated by enhancing monoamine neurotransmission. Targeted neurotransmitters include serotonin and norepinephrine, and a number of medications are available that can selectively enhance the actions of one or both of these substances. Although laboratory tests have validated the pharmacologic effects of these compounds, much less is known about how these effects translate into clinical response. Therapeutic research and experience show clearly that the medications help patients, although the individual and potential cooperative or complementary effects of stimulating each neurotransmitter system remain unclear. Depletion studies have reinforced the validity of targeting these systems and, at the same time, underscored that monoamines most likely are not the only factor driving the clinical presentation of depression.

UR - http://www.scopus.com/inward/record.url?scp=2142715377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142715377&partnerID=8YFLogxK

M3 - Article

C2 - 15046538

AN - SCOPUS:2142715377

VL - 65

SP - 25

EP - 30

JO - The Journal of clinical psychiatry

JF - The Journal of clinical psychiatry

SN - 0160-6689

IS - SUPPL. 4

ER -